OnCo

Sign in to keep your watchlist

Your watched pages live in this browser. Sign in with an email link and OnCo keeps the same list on every device you use. Only your email address and your watchlist are stored.

Goblet cell adenocarcinoma of the appendix: lines of therapy

Cancer page →

4 standard-of-care settings across 4 lines and 1 biomarker subgroup. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.

LineAll comers
Screening, prevention and diagnosis1
Early / localised1
Advanced, first line1
Other settings1

Screening, prevention and diagnosis

SubgroupSettingApproachProducts and trialsEvidence
All comersDiagnosisExpert pathology review with WHO 2019 grading; CT of chest, abdomen and pelvis; colonoscopy; tumour markers; no somatostatin receptor imaging is needed.95

Early / localised

SubgroupSettingApproachProducts and trialsEvidence
All comersLocalised diseaseRight hemicolectomy with lymphadenectomy for all grades; oophorectomy considered in postmenopausal women; adjuvant FOLFOX or CAPOX for node-positive or grade 2 to 3 disease.82

Advanced, first line

SubgroupSettingApproachProducts and trialsEvidence
All comersMetastatic diseaseFOLFOX or CAPOX, then FOLFIRI, as for colorectal adenocarcinoma; somatostatin analogues and platinum-etoposide are not used.82

Other settings

SubgroupSettingApproachProducts and trialsEvidence
All comersPeritoneal metastasesCytoreductive surgery with HIPEC in fit patients with limited disease, with perioperative systemic chemotherapy.82

Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.